542 related articles for article (PubMed ID: 1512329)
1. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
Flaker GC; Blackshear JL; McBride R; Kronmal RA; Halperin JL; Hart RG
J Am Coll Cardiol; 1992 Sep; 20(3):527-32. PubMed ID: 1512329
[TBL] [Abstract][Full Text] [Related]
2. [Antiarrhythmic therapy in patients with heart failure].
Faber TS; Zehender M
Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
[TBL] [Abstract][Full Text] [Related]
3. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
Torp-Pedersen C; Møller M; Bloch-Thomsen PE; Køber L; Sandøe E; Egstrup K; Agner E; Carlsen J; Videbaek J; Marchant B; Camm AJ
N Engl J Med; 1999 Sep; 341(12):857-65. PubMed ID: 10486417
[TBL] [Abstract][Full Text] [Related]
4. Significance and control of cardiac arrhythmias in patients with congestive cardiac failure.
Singh BN
Heart Fail Rev; 2002 Jul; 7(3):285-300. PubMed ID: 12215733
[TBL] [Abstract][Full Text] [Related]
5. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
Bollmann A; Husser D; Cannom DS
Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
[TBL] [Abstract][Full Text] [Related]
6. Can antiarrhythmic drugs survive survival trials?
Pratt CM; Waldo AL; Camm AJ
Am J Cardiol; 1998 Mar; 81(6A):24D-34D. PubMed ID: 9537220
[TBL] [Abstract][Full Text] [Related]
7. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction.
Dries DL; Exner DV; Gersh BJ; Domanski MJ; Waclawiw MA; Stevenson LW
J Am Coll Cardiol; 1998 Sep; 32(3):695-703. PubMed ID: 9741514
[TBL] [Abstract][Full Text] [Related]
8. Antiarrhythmic therapy in heart failure.
Eckardt L; Haverkamp W; Breithardt G
Heart Fail Monit; 2002; 2(4):110-9. PubMed ID: 12634885
[TBL] [Abstract][Full Text] [Related]
9. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.
Singh SN; Fletcher RD; Fisher SG; Singh BN; Lewis HD; Deedwania PC; Massie BM; Colling C; Lazzeri D
N Engl J Med; 1995 Jul; 333(2):77-82. PubMed ID: 7539890
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 in antiarrhythmic therapy : cons position.
Borghi C; Pareo I
High Blood Press Cardiovasc Prev; 2012 Dec; 19(4):207-11. PubMed ID: 23430665
[TBL] [Abstract][Full Text] [Related]
11. A benefit-risk assessment of class III antiarrhythmic agents.
Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
[TBL] [Abstract][Full Text] [Related]
12. Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: a multivariate analysis.
Kaufman ES; Zimmermann PA; Wang T; Dennish GW; Barrell PD; Chandler ML; Greene HL;
J Am Coll Cardiol; 2004 Sep; 44(6):1276-82. PubMed ID: 15364332
[TBL] [Abstract][Full Text] [Related]
13. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Washam JB; Stevens SR; Lokhnygina Y; Halperin JL; Breithardt G; Singer DE; Mahaffey KW; Hankey GJ; Berkowitz SD; Nessel CC; Fox KA; Califf RM; Piccini JP; Patel MR;
Lancet; 2015 Jun; 385(9985):2363-70. PubMed ID: 25749644
[TBL] [Abstract][Full Text] [Related]
14. Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation.
Tuinenburg AE; Van Gelder IC; Van Den Berg MP; Brügemann J; De Kam PJ; Crijns HJ
Heart; 1999 Oct; 82(4):486-93. PubMed ID: 10490566
[TBL] [Abstract][Full Text] [Related]
15. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
[TBL] [Abstract][Full Text] [Related]
16. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm.
Pritchett EL; Kowey P; Connolly S; Page RL; Kerr C; Wilkinson WE;
Am Heart J; 2006 May; 151(5):1043-9. PubMed ID: 16644334
[TBL] [Abstract][Full Text] [Related]
17. Catheter Ablation for Atrial Fibrillation with Heart Failure.
Marrouche NF; Brachmann J; Andresen D; Siebels J; Boersma L; Jordaens L; Merkely B; Pokushalov E; Sanders P; Proff J; Schunkert H; Christ H; Vogt J; Bänsch D;
N Engl J Med; 2018 Feb; 378(5):417-427. PubMed ID: 29385358
[TBL] [Abstract][Full Text] [Related]
18. [Drug prevention of recurrence in paroxysmal and chronic atrial fibrillation].
Hindricks G; Kottkamp H; Willems S; Haverkamp W; Borggrefe M; Breithardt G
Z Kardiol; 1994; 83 Suppl 5():87-96. PubMed ID: 7846950
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients.
Middlekauff HR; Stevenson WG; Stevenson LW
Circulation; 1991 Jul; 84(1):40-8. PubMed ID: 2060110
[TBL] [Abstract][Full Text] [Related]
20. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).
Peters RW; Mitchell LB; Brooks MM; Echt DS; Barker AH; Capone R; Liebson PR; Greene HL
J Am Coll Cardiol; 1994 Feb; 23(2):283-9. PubMed ID: 8294678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
